Which pharmacological feature best distinguishes morphine from codeine among commonly used opioids?

Explanation

## Distinguishing Morphine from Codeine ### Why Option C is Correct **Morphine causes more pronounced respiratory depression at equianalgesic doses** — this is the single most clinically important pharmacological distinction between the two opioids. When doses are adjusted to produce equivalent analgesia (e.g., 10 mg IV morphine ≈ 120 mg oral codeine), morphine's respiratory depressant effect is substantially greater. This difference underpins clinical decision-making: codeine is used for mild-to-moderate pain and cough suppression precisely because it carries a lower respiratory risk at therapeutic doses. ### Why the Other Options Are Incorrect **Option A — "Morphine is a prodrug requiring hepatic metabolism for activation"** This is factually reversed. **Codeine** is the prodrug; it requires O-demethylation by CYP2D6 to morphine for its analgesic effect. Morphine is the active parent compound. This is a classic exam trap. **Option B — "Morphine has a longer half-life and duration of action compared to codeine"** The table below shows this is not a reliable distinguishing feature: | Feature | Morphine | Codeine | |---------|----------|---------| | **Half-life** | 2–4 hours | 2.5–3 hours | | **Duration of action** | 4–5 hours | 4–6 hours | The half-lives and durations are broadly similar; this is NOT a key distinguishing feature. **Option D — "Morphine undergoes hepatic conjugation while codeine undergoes O-demethylation"** This statement is **factually accurate** but is NOT the best pharmacological distinguisher. Both drugs undergo hepatic metabolism; the metabolic pathway difference (Phase II glucuronidation for morphine vs. CYP2D6 O-demethylation for codeine) is a mechanistic detail. Critically, Option D conflates two separate facts without capturing the clinically dominant distinction. The question asks for the feature that **best distinguishes** the two drugs — and respiratory depression at equianalgesic doses is the answer with the greatest clinical and exam relevance. ### Metabolic Summary (for completeness) | Drug | Primary Metabolism | Key Point | |------|--------------------|-----------| | **Morphine** | Phase II glucuronidation → M3G (inactive), M6G (active) | Active parent compound | | **Codeine** | CYP2D6 O-demethylation → morphine; N-demethylation → norcodeine | Prodrug; poor CYP2D6 metabolizers get no analgesia | **High-Yield:** At equianalgesic doses, morphine causes significantly more respiratory depression than codeine — the key clinical and exam discriminator (KD Tripathi 8e, Ch 14). **Clinical Pearl:** Poor CYP2D6 metabolizers (~7% Caucasians, ~1% Asians) derive little analgesic benefit from codeine, while ultra-rapid metabolizers face toxicity risk — a pharmacogenomic consideration unique to codeine, not morphine. [cite: KD Tripathi 8e Ch 14; Goodman & Gilman 13e Ch 20]